NextCure (NASDAQ:NXTC) Trading Up 3.3%

Shares of NextCure, Inc. (NASDAQ:NXTCGet Rating) were up 3.3% during mid-day trading on Thursday . The company traded as high as $4.49 and last traded at $4.43. Approximately 108,372 shares traded hands during trading, a decline of 27% from the average daily volume of 148,640 shares. The stock had previously closed at $4.29.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price target on shares of NextCure from $21.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, May 23rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, NextCure has an average rating of “Moderate Buy” and an average price target of $15.00.

NextCure Trading Up 6.3 %

The company’s 50 day moving average price is $4.50 and its 200-day moving average price is $4.66.

NextCure (NASDAQ:NXTCGet Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.06). As a group, sell-side analysts predict that NextCure, Inc. will post -2.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

Institutional investors have recently modified their holdings of the stock. Silverarc Capital Management LLC grew its position in shares of NextCure by 1.6% during the 1st quarter. Silverarc Capital Management LLC now owns 196,187 shares of the company’s stock valued at $953,000 after buying an additional 3,175 shares during the last quarter. DAFNA Capital Management LLC grew its position in shares of NextCure by 2.3% during the 4th quarter. DAFNA Capital Management LLC now owns 187,696 shares of the company’s stock valued at $1,126,000 after buying an additional 4,205 shares during the last quarter. State Street Corp grew its position in NextCure by 10.7% in the 1st quarter. State Street Corp now owns 57,092 shares of the company’s stock worth $277,000 after purchasing an additional 5,515 shares during the last quarter. UBS Group AG grew its position in NextCure by 224.6% in the 1st quarter. UBS Group AG now owns 9,160 shares of the company’s stock worth $45,000 after purchasing an additional 6,338 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in NextCure by 104.0% in the 1st quarter. JPMorgan Chase & Co. now owns 17,895 shares of the company’s stock worth $87,000 after purchasing an additional 9,121 shares during the last quarter. Institutional investors and hedge funds own 51.83% of the company’s stock.

About NextCure

(Get Rating)

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.

Featured Stories

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.